ERBB2 and breast cancer: The development of BM in patients with breast cancer varies by subtype, with HER2+ and triple-negative breast cancers having the highest propensity of metastasizing to the brain.30,31 In this cohort, patients with HER2+ breast cancer had better survival than patients with HER2− breast cancer.